Page last updated: 2024-11-12

quinoline-3-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

quinoline-3-carboxamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15561101
CHEMBL ID216226
SCHEMBL ID23372
MeSH IDM0536536

Synonyms (17)

Synonym
CHEMBL216226
quinoline-3-carboxamide
6480-67-7
3-quinolinecarboxamide
SCHEMBL23372
3-quinoline-carboxamide
BLTDCIWCFCUQCB-UHFFFAOYSA-N
DTXSID90574189
quinoline 3-carboxamide
bdbm60924
mfcd01366544
CS-0209235
A929404
SB68370
BS-29856
E83240
Z1222423508

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Dose-response data and pharmacokinetic data were used to calculate effective and safe clinical doses of paquinimod."( Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in
Axelsson, B; Bengtsson, AA; Leanderson, T; Lood, C; Ohman, MW; Rönnblom, L; Sparre, B; Sturfelt, G; Tuvesson, H; van Vollenhoven, RF, 2012
)
0.6
" In patients with SLE, the pharmacokinetic properties of paquinimod were linear and well suitable for once-daily oral treatment."( Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in
Axelsson, B; Bengtsson, AA; Leanderson, T; Lood, C; Ohman, MW; Rönnblom, L; Sparre, B; Sturfelt, G; Tuvesson, H; van Vollenhoven, RF, 2012
)
0.6

Dosage Studied

ExcerptRelevanceReference
" Dose-response data and pharmacokinetic data were used to calculate effective and safe clinical doses of paquinimod."( Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in
Axelsson, B; Bengtsson, AA; Leanderson, T; Lood, C; Ohman, MW; Rönnblom, L; Sparre, B; Sturfelt, G; Tuvesson, H; van Vollenhoven, RF, 2012
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
nicotinamide metabolic processNicotinamide N-methyltransferaseHomo sapiens (human)
response to xenobiotic stimulusNicotinamide N-methyltransferaseHomo sapiens (human)
response to organonitrogen compoundNicotinamide N-methyltransferaseHomo sapiens (human)
animal organ regenerationNicotinamide N-methyltransferaseHomo sapiens (human)
methylationNicotinamide N-methyltransferaseHomo sapiens (human)
NAD biosynthesis via nicotinamide riboside salvage pathwayNicotinamide N-methyltransferaseHomo sapiens (human)
positive regulation of gluconeogenesisNicotinamide N-methyltransferaseHomo sapiens (human)
positive regulation of protein deacetylationNicotinamide N-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
nicotinamide N-methyltransferase activityNicotinamide N-methyltransferaseHomo sapiens (human)
pyridine N-methyltransferase activityNicotinamide N-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
cytosolNicotinamide N-methyltransferaseHomo sapiens (human)
cytosolNicotinamide N-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID272370Inhibition of Saccharomyces cerevisiae GCN5 at 0.6 mM2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties.
AID1802032NNMT Enzymatic Activity Assay from Article 10.1021/acs.biochem.6b00733: \\A Rapid and Efficient Assay for the Characterization of Substrates and Inhibitors of Nicotinamide N-Methyltransferase.\\2016Biochemistry, 09-20, Volume: 55, Issue:37
A Rapid and Efficient Assay for the Characterization of Substrates and Inhibitors of Nicotinamide N-Methyltransferase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (9.52)29.6817
2010's16 (76.19)24.3611
2020's3 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.54

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.54 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.54)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.55%)5.53%
Reviews3 (13.64%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]